Aurobindo Pharma: Share transfer for subsidiaries delayed until September 30

Aurobindo Pharma provided an update on the binding agreement for the transfer of shares of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to Curateq Biologics B.V., both wholly owned subsidiaries. This follows a previous agreement entered into on July 29, 2025, with an initial target completion date of August 31, 2025.

The company now reports that the share transfer, initially expected by August 31, 2025, is pending the receipt of an updated business register from authorities in The Netherlands. Consequently, the completion of this share transfer is now scheduled for on or before September 30, 2025. The announcement was submitted to the National Stock Exchange of India Limited and BSE Limited.